ClinicalTrials.gg
RecruitingNCT07567846Updated Nov 5, 2026

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

A Phase 1/2 interventional study of GDC-1261 in Advanced Prostate Cancer and Metastatic Prostate Cancer, sponsored by Genentech, Inc.. Recruiting at 6 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 5, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche — 3 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Hoffmann-La Roche.

Planned enrollment
3rd of 11
260 · median 84
Started
2026
with 1 other
Phase 1/2
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 11th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

03

Conditions studied

  • Advanced Prostate Cancer
  • Metastatic Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of \<=1
  • is >= 3 months
  • or cytologically confirmed prostate adenocarcinoma
  • Disease progression during or following the direct
  • Ongoing androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonist or antagonist, or have had bilateral orchiectomy
  • disease
  • Adequate end organ function

Exclusion criteria

Exclusion Criteria:

  • Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives
  • Structurally unstable bone lesions suggest an impending fracture
  • Untreated central nervous system (CNS) or
  • Uncontrolled pain
  • History of within 5 years
  • Infection requiring systemic IV antibiotics within 14 days or oral antibiotics within 7 days prior to screening, or any evidence of current infection
  • Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Dose Escalation + Expansion

    Participants will receive GDC-1261 as per the schedule described in the protocol.

    Drug: GDC-1261

Interventions

  • DrugGDC-1261

    Participants will receive GDC-1261 as per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 24 months

  2. Incidence and Nature of DLTs Dose-limiting Toxicities (DLTs)

    Time frame: From Day 1-28 of Cycle 1 (1 Cycle = 28 days)

Secondary outcomes

  1. Plasma Concentration of GDC-1261

    Time frame: Up to approximately 24 months

  2. Plasma Concentration of GDC-1261 Either in Fasted or Fed State

    Time frame: Up to approximately 24 months

  3. Prostate-Specific Antigen-30% (PSA30) Response Rate

    Time frame: Up to approximately 24 months

  4. PSA50 Response Rate

    Time frame: Up to approximately 24 months

  5. PSA90 Response Rate

    Time frame: Up to approximately 24 months

  6. Objective Response Rate (ORR)

    Time frame: Up to approximately 24 months

  7. Recommended Dose of GDC-1261

    Time frame: Up to approximately 24 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 19 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
May 5, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Yale Cancer Center · New Haven, United States
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    1 site added
    Show site
    • Yale Cancer Center · New Haven, United States
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07567846
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Apr 29, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: GO46445 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion